Policy | 16 September 2025
FDA launches crackdown on deceptive drug advertising
The FDA is beginning rulemaking to close the “adequate provision” loophole
The FDA is beginning rulemaking to close the “adequate provision” loophole
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Subscribe To Our Newsletter & Stay Updated
